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Background: Cytomegalovirus (CMV) infection in transplant recipients is reported to replicate with a doubling
time of 1.2–2 days, and weekly screening is recommended for early diagnosis. We re-evaluated these features
in our cohort of transplant recipients.
Methods: The CMVdoubling time of theﬁrst CMV infection in theﬁrst year post-transplant could be calculated for
193 recipients of haematopoietic stem cell or solid organ transplantation. Factors determining the proportion of
recipients with a high diagnostic CMV viral load (≥18,200 IU/mL) were explored usingmathematical simulation.
Findings: The overall median doubling time was 4.3 days (IQR 2.5–7.8) and was not inﬂuenced by prior CMV
immunity, or type of transplantation (p N 0.4). Assuming a ﬁxed doubling time of 1.3 days and screening intervals
of 7 or 10 days, 11.1% and 33.3%were projected to have a high CMV viral load at diagnosis, compared to 1.4% and
4.3% if the doubling time varies as observed in our cohort. Consistently, 1.9% of recipients screened weekly had a
high diagnostic virus load.
Interpretation: Screening intervals can be extended to 10 days in cohorts with comparable CMV doubling
time, whereas shorter than 7 days is required in cohorts with shorter doubling times to maintain
pre-emptive screening quality.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cytomegalovirus (CMV) infection is an important cause of complica-
tions in transplant recipients. If untreated, it may progress to CMV
disease, a condition associated with increased morbidity and mortality.
A pre-emptive strategy, comprising of regular screening with CMV PCR
to detect and treat CMV infection before it causes clinical disease, has
therefore become generally accepted (Kotton et al., 2013; Razonable
and Humar, 2013; Andrews et al., 2011; Tomblyn et al., 2009).
A series of longitudinal studies, using measurements of CMV viral
loadwith PCR in transplant recipients, have described the viral dynamics
of CMV in vivo (Bowen et al., 1998; Gor et al., 1998; Cope et al., 1997;
Hassan-Walker et al., 1999; Ghisetti et al., 2004). Subsequent studies
established CMV as a rapidly replicating virus in the human host, with. Lodding).
. This is an open access article undera doubling time ranging from 1 (Emery et al., 1999, 2000, 2002) to
2.3 days (Mattes et al., 2005; Nebbia et al., 2007; Atabani et al., 2012;
Funk et al., 2007; Buyck et al., 2010; Munoz-Cobo et al., 2011). Based
on the assumption of a rapid doubling time, current guidelines
recommend — based on empiric evidence — weekly screening with
CMV PCR when recipients are managed pre-emptively (Kotton et al.,
2013; Razonable and Humar, 2013; Andrews et al., 2011).
“The Management of Post-Transplant Infections in Collaborating
Hospitals” (MATCH) programme was introduced at Rigshospitalet in
Copenhagen, Denmark in 2011,with the aim to reduce the risk of severe
viral diseases in transplant recipients (unpublished data; da Cunha-
Bang, C. et al.). MATCH constitutes a platform for collaboration between
the transplantation units and the Department of Infectious Diseases,
and the associated database contains data on a large cohort of consecu-
tive transplant recipients of both solid organ transplantation (SOT) and
haematopoietic stem cell transplantation (HSCT). Consistent with the
current guidelines, weekly screening intervals for CMV were appliedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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recipients with high viral load at time of diagnosis of the CMV infection
were detected. This raised the question whether the previously deter-
mined CMV doubling time estimates were valid in our cohort.
In this study, the reproducibility of the published doubling time esti-
mateswas investigated. Furthermore, the rationale of aweekly screening
interval with CMV PCRmeasurements in transplant recipients, managed
pre-emptively, was evaluated.
2. Recipients and Methods
2.1. Recipients and Deﬁnition of CMV Infection
Consecutive recipients in the MATCH database transplanted between
January 1 2003 and August 27 2013 (n = 2344), who developed a ﬁrst
CMV infectious episodewithin the ﬁrst 12months following transplanta-
tion, were eligible for inclusion (n = 329). All applicable regulatory and
ethical approvals related to the project are obtained in accordance with
the national legislation.
In order to calculate the CMV doubling time, the episodes needed to
be recordedwith ≥2 quantiﬁable and increasing CMV PCRmeasurements
taken within 14 days of each other (see section Calculation of CMV
Doubling Time and Adjustment for Anti-CMV Treatment) (n = 193).
Although the MATCH programme was initiated in 2011, it was possible
to reconstruct course of events including relevant laboratory assessments
for all recipients since 2003 stored electronically into the MATCH data-
base. A CMV infectious episode was deﬁned as two consecutive quantiﬁ-
able CMV PCR values ≥273 IU/mL (i.e. 300 copies/mL) taken within
2 weeks of each other, or one measurement ≥2730 IU/mL (da Cunha-
Bang et al., 2011). The ﬁrst of two subsequent consecutive negative
CMV PCRs following an infectious episode deﬁnes the end of that
episode. Only the ﬁrst CMV episode was eligible for inclusion, i.e. the
number of included recipients equals the CMV infectious episodes.
2.2. CMV IgG Serostatus
The CMV IgG serostatus for donor and recipient was determined
pre-transplant, and the eligible combinations for inclusion were D+/
R−, D+/R+ or D−/R+. The recipients were stratiﬁed according to
risk of CMV infection depending on donor (D)/recipient (R) CMV IgG
serostatus (positive (+)/negative (−)) prior to transplantation, as
either high-, intermediary- or low risk. The high risk group constituted
of D+/R− for SOT recipients, and D−/R+ for HSCT recipients. D+/
R+ constituted the intermediary risk group for both types of transplan-
tations, and the low risk group D−/R+ for SOT and D+/R− for HSCT.
Due to the small number of recipients in our cohort with low risk
serostatus (n = 13), these recipients were analysed together with the
recipients at intermediary risk.
2.3. CMV DNA Surveillance and Anti-CMV Treatment
This study is based on measurements of CMV in plasma by PCR,
performed on a semi-regular basis as a part of surveillance of CMV in
the MATCH programme. The COBAS Amplicor kit (DiDomenico et al.,
1996) was used until 2011, and since 2011 the COBAS AmpliPrep/
COBAS TaqMan has been used. The Department of Clinical Microbiology
simultaneously tested the two PCR kits, and determined the conversion
factor between the COBAS Amplicor kit and the COBAS AmpliPrep/
COBAS TaqMan to be a factor 1:1. Thus, tomake our resultsmorewidely
applicable we have converted our virus loads into IU/mL using the con-
version factor for the COBAS AmpliPrep/COBAS TaqMan (1 copy/mL
corresponding to 0.91 IU/mL).
The SOT recipients received (val)ganciclovir prophylaxis for
3 months following transplantation and were subsequently treated
pre-emptivelywith (val)ganciclovir in case of CMV infection. In general,
the SOT recipients with serostatus D+/R−, D+/R+ or D−/R+ werescreened monthly in the prophylaxis phase (month one to three post-
transplant), and then weekly in months four to six post-transplant.
Hereafter the recipients are tested monthly until month 12 post-
transplant.
TheHSCT recipientsweremonitoredweekly by CMVPCR fromweek
four to week 17 post-transplant and then at week 19, 26 and 52, except
in case of graft-versus-host disease where weekly monitoring was
continued.
In case of CMV infection (see deﬁnition) treatment with
(val)ganciclovir, or in case of resistance, foscovir (Cunha-Bang et al.,
2013) was initiated.
2.4. Calculation of CMV Doubling Time and Adjustment for Anti-CMV
Treatment
An algorithm was constructed to detect the ﬁrst positive sample of
the infectious episode. This sample is termed V1, and corresponds to
the time t1 (Fig. 1). The algorithm was then constructed to ﬁnd the
highest positive sample within 14 days of the V1 sample; this sample
is termed Vpeak and the time at which it occurs is termed tpeak. The
doubling time is calculated as previously described (Emery et al.,
1999; Atabani et al., 2012). First the CMV growth rate is determined
from the slope of virus over time:
Growth rate ¼ Δ lnVirus load
Δtime
:
The doubling time can then be calculated using the standard expo-
nential function:
Doubling time ¼ ln2
Growth rate
:
Out of the 329 infection episodes, 193 had ≥2 increasing CMV PCR
measurements taken within 14 days of each other. Thus, this formula
was applied to these episodes and the doubling time was calculated.
When calculating the CMVdoubling time, it is necessary to adjust for
any administration of anti-CMV treatment. Information on anti-CMV
treatment was systematically collected for the included CMV infections
from patient ﬁles. For each infectious episode, the proportion of time on
which the calculation of doubling time was based on and that was
covered with anti-CMV treatment, was determined (Fig. 1). Thus this
variable can be between 0% (recipients who didn't receive any anti-
CMV treatment during the time used for calculation for doubling
time) and 100% (recipients who were initiated in anti-CMV treatment
the before or the same day as the V1 sample).
2.5. Modelling CMV Screening Intervals
A mathematical simulation model was constructed to determine
factors that inﬂuence the optimal screening interval for preemptive
treatment. A diagnostic viral load ≥18,200 IU/mL was deﬁned as unde-
sirably high, based on previous clinical experiences and observations
of the prevalence of CMV disease at diagnosis of CMV infection (unpub-
lished data; Lodding, I. et al.). We decided a priori that any monitoring
strategy had to result in ≤5% of the newly developed CMV infections
to be diagnosed at or above this undesirable level. The lower limit of
detection for the CMV PCR assay was set at 273 IU/mL, and the results
were available 24 h after blood draw. The CMV infection was assumed
to emerge randomly within the screening interval, and the doubling
time for the infection was either set at 1.3 days (as reported in the
literature Funk et al., 2007) or allowed to vary as observed in our cohort
(see Resultssection). The observed distribution of doubling time was
either ﬁtted as observed or from best Chi Square ﬁt (ﬁve degrees of
freedom). Based on observations from our cohort, CMV replication
wasmost likely to occur during the ﬁrst 3 months after transplantation,
Fig. 1. Calculation of doubling time and adjustment of anti-CMV treatment. An algorithmwas constructed to detect the ﬁrst positive sample of the infectious episode, termed V1 and cor-
responding to the time t1. The highest samplewithin 14 days of the V1 samplewas then detected; this sample is called Vpeak, and it corresponded to the time tpeak. The doubling time could
then be calculated. The proportion of time used for calculation of doubling time covered with anti-CMV treatment was determined based on data on anti-CMV treatment collected from
patient ﬁles.
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ﬁrst 3 months after the prophylaxis was discontinued. The model is
presented in detail in Appendix A.
The mathematical projection allowed us to explore the impact of
different cut-offs for undesirably high virus load, different estimations
of doubling time (estimations based of our cohort as well as previously
described), and different screening intervals.
2.6. Validation of the Output From the Mathematical Model
In order to illustrate the impact of a weekly screening interval in our
own cohort, the number of ﬁrst-time infections that were preceded by a
previous negative CMV PCR exactly 7 days earlier, was identiﬁed.
Among these, the percentage diagnosed with an undesirably high viral
load was calculated.
2.7. Statistical Methods
Differences in doubling time were explored using standard descrip-
tive statistics, including correlation analyses and Mann Whitney U.
Double sided p-values were used, and results were considered statisti-
cally signiﬁcant at a level of b0.05.
3. Results
3.1. Patient Characteristics and Features of CMV Infection
The CMV doubling time could be estimated for 193 of the 329
recorded infectious episodes in MATCH. The excluded infectious
episodes had a larger proportion of females (43% vs 33%), and SOT
recipients (56% vs 38%) than the included infectious episodes (online
Appendix B). Distribution of CMV IgG serostatus and virological proﬁles
were comparable between the groups.
38% of the included 193 infectious episodes represented SOT
recipients, and 62% HSCT (Table 1). The median age at transplantation
was 46 years (IQR 32–58), with a majority of males (69%). Due to the
different strategies for prevention of CMV disease in the SOT and HSCT
recipients (SOT recipients receiving primary chemoprophylaxis with
(val)ganciclovir for theﬁrst 3months followed by pre-emptive strategy,
and HSCT recipients managed solely pre-emptively), the time of
emergence of the CMV infections occurred later in SOT recipients
compared to the HSCT recipients (109 days vs 50 days, respectively,
Table 1). Conversely, the median number of days between the V1 and
the Vpeak samples was 7 days and themedian viral load of the V1 samplewas 1183 IU/mL for all groups. SOT recipients reached a higher median
Vpeak compared to the HSCT recipients (p = 0.05).
Risk of CMV infection was evenly distributed, overall 50% had high
risk and 50% had intermediary or low risk of CMV infection. This distri-
bution was not inﬂuenced by type of transplantation.
A total of 56 recipients did not receive any treatment during the
follow-up time when the CMV PCR measurements used to determine
the doubling time was determined. For an additional 21 patients, treat-
mentwas provided throughout this follow-up time. Among the remain-
ing 116 recipients, treatment was provided during some of the follow-
up time.
The median proportion of time that was used for calculation of
doubling time and that was covered with anti-CMV medication was
50% (IQR 0–80%) (Table 1). For 21 recipients medication was ongoing
throughout the entire period used for doubling time estimation either
because of breakthrough on primary prophylaxis (ten kidney and two
lung transplant recipients) or because of initiation of empiric therapy
due to strong clinical suspicion (six HSCT and two SOT). Out of the 12
SOT recipients with breakthrough on prophylaxis, eight progressed to
CMV disease, and in one case, sub-optimal dosages of the prophylactic
treatment lead to the selection of ganciclovir-related drug mutations.
This case was published in Am J of Transplantation in 2013 (Cunha-
Bang et al., 2013). Overall, 59 (31%) of the recipients developed CMV
disease (Table 1).
3.2. CMV Doubling Time
The median doubling time was 4.3 days (IQR 2.5–7.8) (Fig. 2). This
estimate persisted after stratifying for risk of CMV infection according
to pre-transplant CMV IgG D/R serostatus, and type of transplantation
(p N 0.4). The CMV doubling time was similar for different years of
transplantation (p N 0.05, data not shown). There was no correlation
between the doubling time and the Vpeak (r = −0.02), and this was
also observed after stratifying for type of transplantation as well as
risk of CMV infection associated with CMV IgG serostatus (p N 0.2).
When calculating the CMV doubling time for the 56 infectious episodes
that didn't receive any treatment during the interval used for calculation
of doubling time was 4.1 (IQR 2.2–10.7) days. Comparing the doubling
time of the 56 patients without treatment with the doubling time of
the 137 recipients that did receive treatment at some point during
the time used for calculation of doubling time, this was statistically
insigniﬁcant (p = 0.99).
A total of 59 patients developed CMV disease. The doubling time in
those that developed versus those that did not develop CMV disease
Table 1
Characteristics of transplant recipients at the time of transplantation and clinical parameters of subsequent CMV infection, according to type of transplantation.
All recipients Type of transplantation p-Value
Solid organ Bone marrow
Patient characteristics at the time of transplantation
Demographics
Number (%) of recipients 193 (100%) 74/193 (38%) 119/193 (62%)
Median age (IQR), years 46 (32–58) 51.5 (38–59) 45 (23–56) 0.03
Gender (% male) 133/193 (69%) 48/74 (65%) 85/119 (71%) 0.3
Risk of CMV infection1
Number of recipients at high risk of CMV infection 96/193 (50%) 34/74 (46%) 62/119 (52%) 0.5
Number of recipients at intermediary/low risk of CMV infection 97/193 (50%) 40/74 (54%) 57/119 (48%) 0.6
Factors describing CMV infection
CMV infection
Median time-span from tx to the V1 sample2 (IQR), days 55 (42–105) 109 (46–151) 50 (40–61) b0.0001
Median time-span from the V1 sample to Vpeak sample2 (IQR), days 7 (4–11) 7 (5–11) 7 (4–11) 0.4
Median viral load (IU/mL), V1 sample (IQR) 1183 (546–3913) 1183 (455–8099) 1183 (601–3367) 0.6
Median viral load (IU/mL) of Vpeak sample (IQR) 5460 (1820–26,390) 9965 (1911–40,040) 4550 (1729–15,470) 0.05
Anti-CMV treatment
Strategy for prevention of CMV disease 3 months prophylaxis +
preemptive treatment
Preemptive treatment
Number of patients not receiving treatment during the period of
infection used for calculation of doubling time3
56/193 (29%) 29/74 (39%) 27/119 (23%) 0.01
Number of patients experiencing infectious breakthrough during
prophylaxis or treatment
21/193 (11%) 15/74 (20%)4A 6/119 (5%)4B 0.002
Median proportion of time during CMV infection on treatment (IQR)3 50% (0–80%) 18% (0–85%) 57% (0–80%) 0.1
Symptomatic CMV infection5
Number of patients with symptomatic CMV infection 59/188a (31%) 33/74 (45%) 26/114a (23%) 0.002
Risk factors for development of CMV infection
Allograft rejection or graft versus host disease6 36/193 (19%) 8/74 (11%) 28/119 (24%) 0.04
Abbreviations: CMV; cytomegalovirus, tx; transplantation, IQR; interquartile range.
1 Risk of CMV infection according to donor (D)/recipient (R) CMV IgG serostatus (+/−) at the time of transplantation. For solid organ transplantation recipients D+/R− is associated
with high risk of CMV infection, while D−/R+ is associated with low risk. Among bone marrow transplant recipients, D−/R+ is associated with a high risk of CMV infection,
whereas D+/R− is associatedwith a low risk. For both types of transplantation, D+/R+ is associatedwith intermediary risk of CMV infection. Due to the low number of low risk patients
in our cohort (N = 13), intermediary and low risk patients are grouped together in this table.
2 V1 is the ﬁrst positive CMV PCR of the infectious episode, Vpeak is the highest measured CMV PCR sample within 14 days of V1.
3 When calculating CMV doubling time, the V1 sample and the Vpeak sample, are used. Based on this time span, the proportion of time during CMV infection on treatment has been
determined for each patient.
4 A. Of these, 10 kidney- and two lung recipients had prophylaxis breakthrough; for one lung and two kidney recipients treatmentwas initiated before conﬁrmation of positive CMVPCR
due to strong clinical suspicion of CMV infection. B. The latter was also the case for the six HSCT patients.
5 Deﬁned as either CMV syndrome (fever, leukopenia or malaise due to CMV infection) or CMV disease (pneumonia, enteritis, hepatitis, encephalitis or retinitis veriﬁed to be caused by
CMV).
6 Allograft rejection or graft versus host disease conﬁrmed with biopsy within 30 days prior to the ﬁrst positive CMV PCR to the date of the highest measured CMV PCR.
a For ﬁve HSCT recipients, these data were unavailable.
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The calculated CMV doubling times of the cohort ﬁtted well to a Chi
Square distribution (Fig. 3). The infectious episodes were divided into
four quartiles based on the doubling time (Fig. 3 and Table 2). ThisFig. 2. The estimated CMV doubling time for all infectious episodes, stratiﬁed for type of
transplantation and risk of CMV infection. Circles indicate the median doubling times
and bars show the interquartile ranges. Abbreviations: SOT; solid organ transplantation,
HSCT; heamatopoietic stem cell transplantation.allowed for careful comparison of the recipients on the basis of the
CMVdoubling times of each quartile. No signiﬁcant differences between
the quartiles of the infectious episodes were detected when comparing
factors such as age, gender, typeof transplantation, risk of CMV infection
associated with CMV IgG serostatus, and, for proportion of time on anti-
CMV treatment during the interval used for calculation of doubling time
(p N 0.2). There was no signiﬁcant difference between the quartiles
when assessing the proportion of rejection episodes or graft-versus-
host disease (p = 0.4). There was a signiﬁcantly higher proportion of
symptomatic CMV infection when comparing the ﬁrst quartile to the
second, however, this was not persistent when comparing the ﬁrst
quartile to the two other quartiles (p N 0.1).
3.3. Simulation of CMV Screening Interval
Amathematicalmodel was constructed to determine the proportion
of ﬁrst CMV infections that was diagnosed with an undesirably high
viral load. This proportion depended on the assumed doubling time
and the test periodicity in the screening interval (Table 3).When apply-
ing a ﬁxed doubling time of 1.3 days (Funk et al., 2007), approximately
11% (95% CI 10.1–11.9%) of the recipients would risk being diagnosed at
a high viral load if a 7 day screening interval was used and 33% (95% CI
31.7–34.3%) if the screening interval was extended to 10 days, taking
into consideration that an additional extra day is needed for laboratory
processing. In comparison, using the varied doubling time estimates
from our cohort, only 1.4% (95% CI 1.07–1.72%) and 4.3% (95% CI 3.73–
Fig. 3. Distribution of the variation in CMV doubling time in the cohort. Cumulative prob-
ability of the unique 193 doubling times of the cohort is plotted and ﬁtted to a Chi Square
distribution. The infectious episodes could based on this plot be divided into four quartiles
based on the doubling time, where the 1st quartile represent the fastest doubling times,
and the 4th the slowest.
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ably high viral load when applying a 7 or 10 day screening interval.
108 recipients had an infectious episode where the V1 sample was
preceded by a previous negative CMV PCR exactly 7 days earlier, and
among these, two recipients (1.9%) had an undesirably high viral load
upon detection of the infection.
4. Discussion
In this study the overall CMV doubling time was longer and more
varied than previously reported (Emery et al., 1999, 2000, 2002;
Mattes et al., 2005; Atabani et al., 2012; Buyck et al., 2010). Furthermore,
we present a simulation of factors that help determine an optimal inter-
val between CMV PCR screenings as part of a pre-emptive strategy
aimed at diagnosing CMV infection while the viral load remains below
a deﬁned threshold. Furthermore, one of the model estimates was
conﬁrmed to be consistent with observed data. The output from our
model question the current recommendation based on previously
reported doubling time estimates (Emery et al., 1999, 2000, 2002) of
weekly screening (Kotton et al., 2013; Tomblyn et al., 2009), as we
project that such a short doubling timewould generate an unacceptably
high proportion (N10%) of recipientswith an undesirably high viral load
at diagnosis. Only intervals shorter than 7 days would lower this
proportion to b5%. Conversely, in cohorts of transplant recipients with
doubling times similar to ours, our model suggest that the interval
between screening can be extended to 10 days while still preserving aTable 2
Characteristics of recipients stratiﬁed for quartile of CMV doubling time.
Characteristics 1st quartile
N = 49
Median CMV doubling time (IQR), days 1.7 (1.4–2.1)
Median age, years (IQR) 51 (34–62)
Gender (proportion of males) 36/49 (73%)
Median proportion of time during CMV infection on treatment (IQR) 0.33 (0–0.75)
Type of transplantation
Proportion of SOT recipients 22/49 (45%)
Proportion of HSCT recipients 27/49 (55%)
Risk of CMV infection
Proportion at high risk 28/49 (57%)
Proportion at intermediary/low risk 21/49 (43%)
Median V1 (IQR) IU/mL 1001 (455–3640)
Median Vpeak (IQR) IU/mL 18,200 (4186–58,2
Proportion of recipients with symptomatic CMV infection1 22/48 (46%)
Proportion of recipients with allograft rejection or GVHD 7/49 (14%)
1 For ﬁve HSCT recipients, data regarding CMV disease was unavailable.
⁎ Themedian V1was not signiﬁcantly different when comparing the 1st, 2nd and 3rd quar
p = 0.02.
⁎⁎ There was a signiﬁcantly higher proportion of symptomatic CMV infection when comparin
quartile to the two other quartiles (p N 0.1).proportion of ﬁrst infections diagnosed with an undesirably high viral
load below 5%.
Several researchers have attempted to estimate the doubling time
for CMV infection. Using a similar mathematical approach, our results
suggest that the doubling time is substantially longer and more varied.
This raises the question of whether the populations or the virus studied
in these investigations are intrinsically different to ours.We used a com-
bined cohort of SOT and HSCT recipients, who received different prima-
ry CMV chemoprophylaxis and intensity of immunosuppression, but
found the doubling time to be comparable. Our hospital doesn't routine-
ly use T-cell depletion through administration of anti-CD52 antibodies.
Thus, it may be possible that our cohort on average is less immune
deﬁcient than cohorts reported from the United Kingdom where such
antibodies are more frequently used (Tauro et al., 2005). Our ﬁndings
warrant future cross-site comparative studies to further elucidate
potential explanations.
Anti-CMV treatment was given to some of the recipients in our
cohort during the follow-up time used to estimate the CMV doubling
time, but the doubling time estimate was unaffected by this. Most
CMV particles are present outside the blood compartment (Plachter
et al., 1996; Jarvis and Nelson, 2002), and hence plasma levels of
CMV-DNA predominantly reﬂect wash-out from those compartments.
Thus, it is not surprising that use of anti-CMV medication doesn't affect
early kinetic changes in plasma CMV-DNA levels after the infection is
ﬁrst diagnosed and treatment is initiated. Previous studies have
suggested that blood CMV-DNA may continue to increase the ﬁrst
2 weeks after initiation of anti-CMV treatment (Nichols et al., 2001;
Park et al., 2011).
Most of the previously published work is based on CMV PCR
measurements in whole blood (Emery et al., 1999, 2000, 2002; Mattes
et al., 2005; Atabani et al., 2012; Buyck et al., 2010), and not plasma as
in our study. Whole blood contains more DNA than plasma, and virus
loads are typically higher in whole blood compared to plasma (Lisboa
et al., 2011). However, the relationship between consecutive CMV PCR
samples should be the same regardless of whether they are measured
in whole blood or plasma (Lisboa et al., 2011; Razonable et al., 2002),
making it less likely that our calculated doubling time is explained by
this methodological difference.
Intrinsic variation in the CMV PCR assay could tend to lead to larger
variation in estimating the CMV doubling time. We used commercial
and standardized assays (the COBAS Amplicor kit and the COBAS
AmpliPrep/COBAS TaqMan) (DiDomenico et al., 1996), and our internal
calculation suggests that the variation of the PCR kit is maximally
0.5 log10 (data not shown). Thus, it is unlikely that the used CMV PCR2nd quartile 3rd quartile 4th quartile p-Value
N = 48 N = 48 N = 48
3.4 (2.9–3.9) 5.6 (4.7–6.6) 12.0 (9.2–21.2)
47.5 (33–58) 47 (24–57) 45 (36–54.5) 0.7
31/48 (65%) 34/48 (71%) 32/48 (67%) 0.3
0.43 (0–0.81) 0.62 (0.21-0.85) 0.61 (0–0.85) 0.3
15/48 (31%) 15/48 (31%) 22/48 (46%) 0.2
33/48 (69%) 33/48 (69%) 26/48 (54%) 0.2
20/48 (42%) 28/48 (58%) 20/48 (42%) 0.2
28/48 (58%) 20/48 (42%) 28/48 (58%) 0.2
1147 (546–3076) 915 (455–4596) 1911 (814–14,560) 0.02⁎
40) 5779 (1957–17,290) 3044 (1456–12,376) 3504 (1124–31,987) 0.01
9/46 (20%) 14/47 (30%) 14/47 (30%) 0.01⁎⁎
9/48 (19%) 10/48 (21%) 10/48 (21%) 0.4
tiles. The 4th quartile had a signiﬁcantly higher V1 sample compared to the 1st quartile,
g the 1st quartile to the 2nd, however this was not persistent when comparing the 1st
Table 3
Proportion of recipientswith an undesirablya high CMV virus load, when applying a pre-emptive strategy to prevent CMV disease depending on intervals between CMV PCR screening and
the assumed doubling time of the CMV infections.
Intervals between screening with CMV PCR as part of a pre-emptive strategy to detect emerging
CMV infection (days)b
7 10 14
Assumed doubling time: Estimated % of recipients having undesirably high CMV viral load (IU/mL)a if the infection develops during the screening interval
31 h — no variation 11.1 33.3 50.0
Varied as observed in our cohort 1.4 4.3 8.7
a Assuming that the doubling time (and possible variation hereof) is as depicted in the left column, infections emerges randomly during the screening interval, and the aim of the pre-
emptive strategy is to detect the infection before the virus reach an undesirably high viral load of N18,200 IU/mL.
b 7 days is currently the recommended standard; it is assumed that the results of the screening test are available 24 h later (the day displayed + 1).
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by others. Future studies focused on estimating CMV doubling time are
encouraged to perform daily sampling which would collectively reduce
this problem.
We used consecutive CMV infection episodes as basis for estimating
the CMV doubling time, although this was only possible for 193 of the
329 ﬁrst time CMV infections that emerged in our cohort. The excluded
episodes typically occurred before the initiation of the MATCH
programme. Thus, these episodes were not as rigorously screened,
and they contained more SOT recipients. However, key virological
parameters such as the Vpeak did not signiﬁcantly differ, and the includ-
ed material is considered representable of the cohort.
Conversely, intentional selection has been reported but not quanti-
ﬁed in previous studies, where the doubling time for recipients who
had b3 fold increase in CMV virus load or for recipients who had a
self-limiting infectious episodes was not calculated (Munoz-Cobo
et al., 2011; Gimenez et al., 2014). Such selection may preferentially
include recipients experiencing rapid replication, while excluding
recipients with a less dramatic increase in virus load.
The cut off for undesirably high virus load was set to N18,200 IU/mL.
This is an arbitrary decision based on both clinical experience and an
ongoing study at our hospital on the prevalence of CMV disease at CMV
diagnosis. The goal of the pre-emptive strategy at our hospital is to diag-
nose CMV infections while the viral load is below this threshold, as data
fromour hospital suggest that the prevalence of CMV disease at diagnosis
is substantially higher (N20 fold) if the infection is diagnosedwith a virus
loadN18,200 IU/mL (unpublisheddata; Lodding, I. et al.). This observation
is also consistent with that of the previous literature (Gor et al., 1998;
Cope et al., 1997; Hassan-Walker et al., 1999). However, when applying
the tool for estimation of the optimal screening interval provided in Ap-
pendix B, clinicians may choose another threshold for undesirably high
virus load depending on their own clinical experiences and preferences.
Our simulation model provides an independent conﬁrmation of the
CMV doubling time we estimated. The model derives a proportion of
CMV infections diagnosed with an undesirably high CMV viral load
when screening the cohort every 7 days to be comparable with what
we actually observe in our cohort. With this conﬁrmed ﬁxed point in
mind, it is intriguing that our model would predict an unacceptably
high proportion of diagnosis being made with an undesirably high
CMV viral load had the original estimates of the doubling time in fact
been correct. As most transplantation units world-wide are adhering
to and are comfortable with the 7 day interval, this also indirectly
suggest that previous estimates of the CMV doubling time may be too
short.We encourage other transplantation units to present the distribu-
tion of their diagnostic viral loads and to consider using our simulation
model (enclosed as Appendix A) and possibly engage in collaboration
with us to further reﬁne this tool.
In summary, we provide new insight into the estimation of the
doubling time of CMV infection in transplant recipients, and its clinical
applicability. This reportmay result in a better understanding of virolog-
ical and clinical aspects of this frequent and important complication in
the immune deﬁcient host.Contributions
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